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The concept of dedifferentiation had previously been used in salivary gland carcinomas. Recently, the term “high-grade
transformation” was introduced for adenoid cystic carcinoma, acinic cell carcinoma, epithelial-myoepithelial carcinoma, and
polymorphous low-grade adenocarcinoma and may better reflect this phenomenon, although transformation into moderately
differentiated adenocarcinoma (i.e., not “high grade”) has also been described. Among the immunohistochemical markers, Ki-
67 seems to be the only one that can help distinguish between the conventional and transformed components; however, the
combination of morphological criteria is still sovereign. The overexpression of p53 was observed in the transformed component in
all tumor types studied, despite few cases having been demonstrated to carry mutations or deletions in TP53 gene. Genetic studies
in salivary gland tumors with dedifferentiation/high-grade transformation are rare and deserve further investigation. This paper
aims at providing an overview on the recent concepts in histopathological classification of salivary gland tumors, complemented
by immunohistochemical and genetic findings.
1. Introduction
The concept of dedifferentiation was first proposed by Dahlin
and Beabout in 1971 [1], when they described dedifferenti-
ated chondrosarcoma as a distinct clinicopathologic entity
characterized by a low-grade chondrosarcoma juxtaposed
to a histologically different high-grade sarcoma [1]. Lately,
dedifferentiation has been recognized in a variety of salivary
gland carcinomas, including adenoid cystic carcinoma [2],
mucoepidermoid carcinoma [3], myoepithelial carcinoma
[4], epithelial-myoepithelial carcinoma [5], and acinic cell
carcinoma [6].
Dedifferentiation is the progression of cells towards a less
differentiated state in which the original line of differenti-
ation is no longer evident [7]. The term dedifferentiation
might not be properly used in epithelial tumors, especially
when the dedifferentiated component is still recognizable
as carcinoma or adenocarcinoma [8]. Recently, Seethala et
al. introduced the term “high-grade transformation” for
adenoid cystic carcinomas. This term better reflects the fact
that the dedifferentiated component often maintains some
features of the original tumor, such as glandular differ-
entiation [8–10]. In recent studies, our group and others
have demonstrated that adenoid cystic carcinomas can also
undergo transformation to adenocarcinomas which are not
poorly differentiated, suggesting that also the term “high-
grade transformation” may not be adequate, at least in the
case of adenoid cystic carcinoma [11, 12].
Although considerable progress has been made in elu-
cidating the genetic events that underlie the progression of
many malignancies, those involved in salivary gland tumors
are still poorly understood and the relationship between his-
tological progression and genetic events is not well defined.
The general theory of monoclonal evolution assumes that
the mutational complexity of a tumor increases with time
and, therefore, tumor genomes with the fewest chromosome
aberrations contained the earliest mutations in tumor pro-
gression [13, 14]. In contrast, high-resolution comparative
genomic hybridization (CGH) microarrays have been used
to study the genome structure of heterogeneous breast
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tumors and shown that they progress by different genomic
rearrangement patterns [15]. Thus, the genomic heterogene-
ity can be ascribed to genetically distinct subpopulations,
which contain a set of common mutations (early events)
that are inherited and persistent throughout their evolution,
while events unique to the profiles are late [16]. However,
genetic alterations cannot solely explain the histological
heterogeneity in tumors. Epigenetic alterations, such as DNA
hypomethylation in tumor cells, cause chromatin deconden-
sation and chromosomal rearrangements that may result in
chromosomal instability. Moreover, DNA hypermethylation
of CpG islands near the promoter regions silences specific
genes including tumor suppressor genes in cooperation with
histone modification [17]. Therefore, the histological hetero-
geneity could also involve modifications of epigenetic switch.
This paper will give an overview on the recent concepts
in histopathological classification of salivary gland tumors in
which dedifferentiation/transformation has been described:
adenoid cystic carcinoma, acinic cell carcinoma, epithelial-
myoepithelial carcinoma, polymorphous low-grade adeno-
carcinoma, mucoepidermoid carcinoma, and myoepithelial
carcinoma. Below follows a one-by-one description of these
tumors, and emphasis will be placed on immunohistochem-
ical and genetic findings.
2. Clinical and Morphological Features
Since dedifferentiation/transformation is extremely rare,
there are few data to establish how the prognosis compares
to that of their conventional counterparts. Several clinical
features have proven to be relevant, such as lymph node
metastasis in adenoid cystic carcinoma and acinic cell
carcinoma [8, 9], recurrence in polymorphous low-grade
adenocarcinoma and mucoepidermoid carcinoma [3, 18],
and metastasis in epithelial-myoepithelial carcinoma [10].
The majority of adenoid cystic carcinoma (AdCC) with
transformation occurs during the sixth decade or later and
most commonly involves the sinonasal mucoserous glands,
palate, and submandibular glands. This tumor shows a
slight male predominance, unlike conventional AdCC, and
is often detected at an advanced stage due to extraglandular
or bone involvement. One of the most important clinical
features is the high propensity for lymph node metastasis
(57% versus 5–25% in conventional AdCC), suggesting that
this tumor should be also placed in the high-risk category
for neck dissection [8, 19]. Until the time of writing, the
literature revealed a total of 36 cases [2, 11, 12, 20–28]. The
median survival of the largest reported series of AdCC with
transformation, in which all cases were poorly differentiated
carcinomas, was estimated at 12 months [8]. However, AdCC
with transformation into moderately differentiated adeno-
carcinoma seems to present a slower course (in some cases
comparable to conventional AdCC), in contrast to AdCC
with transformation into poorly differentiated carcinoma
which usually shows a more aggressive clinical course [11,
12]. Seethala et al. were the first to establish morphological
criteria for differentiating AdCC with high-grade transfor-
mation [8]. At least three major criteria are required, prolifer-
ation of tumor cells with at least a focal loss of myoepithelial
cells surrounding tumor nests, nuclear size at least 2-3
times the size of tubular/cribriform AdCC nuclei, thickened
irregular nuclear membranes, and prominent nucleoli in
a majority of cells. The squamous areas, micropapillary,
and the loss of myoepithelial differentiation are considered
unique morphological findings in the area transformed [8].
Based on the degree of gland formation (differentiation),
cellular pleomorphism, and mitotic activity, Bonfitto et al.
and Costa et al. classified the transformed components into
moderately differentiated adenocarcinomas (when at least
2/3 of the transformed component presented gland forma-
tion) and poorly differentiated carcinomas (gland formation
was scarce or absent) [11, 12]. These morphological features
are observed in Figure 1. The literature does not suggest a
minimum percentage of the transformed component [8].
The first acinic cell carcinoma (AcCC) with dedifferen-
tiation/high-grade transformation of salivary gland was
reported by Stanley et al., in 1988 [6]. Thirty-five cases
have been described in the literature [6, 9, 29–41] and
most of them showed poor clinical outcome, but in 3
cases it was described to remain unclear [29, 42, 43]. All
cases reported to date were of parotid gland origin with
involvement of both the superficial or deep lobes. Especially
those AcCCs in the deep parotid lobe have been associated
with a poor clinical outcome [35]. The median age of 58
years is higher than that reported for conventional AcCC,
44 years [34]. In contrast with its conventional counterpart,
AcCC dedifferentiation/high-grade transformation shows a
slight male predominance, high recurrence rate, and high
propensity for cervical lymph node metastasis, suggesting a
role for neck dissection in management of patients [9, 35].
Dedifferentiated AcCC (Figure 2) generally shows con-
ventional low-grade AcCC juxtaposed with high-grade carci-
noma, which may be either poorly differentiated adenocarci-
noma or undifferentiated carcinoma. Both solid and micro-
cystic patterns of AcCC have been described in the low-grade
component. The high-grade component generally shows a
population of anaplastic cells with abundant cytoplasm,
large polymorphic nuclei, and loss of acinar differentiation.
Furthermore, comedonecrosis and vascular and perineural
invasion are typically observed in AcCC [6, 9, 35, 36, 38].
Epithelial-myoepithelial carcinoma (EMC) is a biphasic
tubular neoplasm of clear myoepithelial cells surrounding
small lumina lined by ductal epithelial cells. Typically, this
is a low-grade malignancy that mainly occurs in the parotid
gland and exhibits distinctive subtypes including tubular,
papillary, cystic, and solid patterns [44]. In EMC, myoepithe-
lial as well as ductal epithelial cells can transform into a high-
grade carcinomatous component [10] which has gone under
a variety of terminologies such as high-grade carcinoma
[45, 46], dedifferentiated [5, 47–50], myoepithelial anaplasia
[48], and myoepithelial carcinoma arising in EMC [2].
Recently the term “EMC with high-grade transformation”
has been proposed for the all lesions where a more aggressive
carcinoma is observed regardless whether it originated as
a gradual transition or an abrupt transformation of the
ductal or myoepithelial component [10]. The reasons for the
adoption of this term were the difficulties in defining criteria
for the cellular classification of the high-grade component,
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Figure 1: Adenoid cystic carcinoma with transformation to a moderately differentiated adenocarcinoma (a) and (b) and to poorly
differentiated carcinoma (c) and (d). (a) and (b) H&E original magnification 200x and (c) and (d), 400x.
(a) (b)
(c) (d)
Figure 2: Acinic cell carcinoma with high-grade transformation to undifferentiated carcinoma. (a) and (b); (c) Conventional component;
(d) high-grade transformed component. (a) PAS original magnification 1000x; (b) H&E original magnification 100x; (c) and (d), H&E
original magnification 400x.
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the possibility that some tumors may have features of both
cell types, and the fact that these lesions uniformly show
worse prognosis than typical EMC.
A common feature in many of transformed EMC also
is a history of indolent growth prior to the development of
transformation [50]. Patients with EMC containing high-
grade transformation were older than conventional EMC
patients (mean 75.9 years) and most commonly involved
the parotid glands, with frequent extraglandular extension.
Of all 17 cases reported in the literature, 61.5% were
female versus 38.5% males. They appeared more aggressive
than conventional EMC, mainly due to high propensity for
lymph node and distant metastasis, prominent infiltrative
growth pattern, and higher proliferative activity. However,
little follow-up information is available, with a mean of
27.6 months (range: 3 to 72 months). The worse prognosis
suggests the need for wider excision, neck dissection, and
adjuvant radiotherapy [5, 10, 45–50].
Five cases of polymorphous low-grade adenocarcinoma
(PLGA) with transformation to high-grade carcinoma
described in the literature showed significant similarities in
the morphology and in the origin, minor salivary gland
of palate. These cases underwent transformation to poorly
differentiated adenocarcinomas characterized by a predom-
inantly solid and cystic growth pattern, nuclear atypia with
prominent nucleoli and foci of necrosis [18, 51, 52] Lloreta
et al. described one more case originating in the nasal cavity
and adjacent sinuses with extensive areas of undifferentiated
carcinoma consisting of compact epithelial cell nests with
central necrosis [53]. The histological transformation seems
to have occurred after a protracted clinical course with mul-
tiple recurrences, a late phenomenon in tumor progression
[18, 52]. The possible role of radiation therapy as an initiator
of this transformation may have been important in the
three of the five published cases of transformation in PLGA
[51, 52]. Despite the fact that high-grade transformation is
recognized as an event with a more aggressive clinical course,
only one case of PLGA in the literature died in consequence
of the disease [53] and none showed metastasis thereafter
[18, 51, 52].
The only two cases reported of dedifferentiated mucoepi-
dermoid carcinoma (MEC) in the literature both presented a
biphasic histology comprising a high-grade component and
a low grade component separated by a transition zone [3, 54].
The high-grade component exhibited solid nests and sheet-
like growth patterns, without glandular or cystic structures.
Sheets of undifferentiated anaplastic or sarcomatoid growth
with marked pleomorphism, frequent mitoses (>50%), and
extensive necrosis were also observed (Figure 3) [3, 54].
The first case described by Nagao et al. concerned a
55-year-old man with a parotid gland tumor. Despite two
recurrences within a short period after surgery, the patient
remained alive during the next 10 years [3]. The second
case of an 11-year-old girl located in trachea, conversely,
rapidly metastasized to pleura, mediastinal lymph nodes,
abdominal wall and vertebral bones leading to death in <3
months from diagnosis [54]. With few cases in the literature,
it is difficult to establish clinical correlations in relation
to the conventional MEC, but dedifferentiated MEC seems
to reach the same broad age range as the conventional
counterpart.
One case of dedifferentiated myoepithelial carcinoma
(MCa) was described by Ogawa et al. in 2003 [4]. Two his-
tologically distinct neoplastic cell populations were observed
in the multinodular tumor of parotid gland. The first popu-
lation was diagnosed as low-grade MCa and occupied more
than 80% of the tumor. The second population consisted of
polygonal or short spindle cells with pleomorphism as well as
infiltration and high mitotic rate suggesting undifferentiated
carcinoma. Moreover, these tumor cells lost the immunohis-
tochemical characteristics of myoepithelial differentiation. A
59-year-old man presented first recurrence in the primary
site after 5 months and a second one was observed 4 months
later, although radiation therapy was used. The patient is
alive and metastasis was not recognized [4].
3. Immunohistochemical Profile
3.1. Myoepithelial Markers. Myoepithelial cells exhibit dual
epithelial and smooth muscle characteristics and tradition-
ally are stained with antibodies against myoid proteins,
such as α-smooth muscle actin (α-SMA), muscle-specific
actin (HHF35), vimentin, or calponin. Recently, p63 has
become a popular marker for abluminal cells (basal cells and
myoepithelial cells) [55–57]. In tumors with myoepithelial
component, such as AdCC and EMC, the participation
of myoepithelial cells in the dedifferentiated/high-grade
transformed areas seems to differ markedly. In AdCC, the
loss of myoepithelial component has been used as one of
the major criteria to identify the transformed areas [8].
Thus the expression of p63, α-SMA, and calponin should
be absent or at least focal in the high-grade component
[8]. In contrast, in EMC the myoepithelial participation
appears to be important in the high-grade component
[10], although the cells show a heterogeneous expression
of the myoepithelial markers (Table 1). S-100 protein and
p63 have been found to be diffusely or focally positive in
the transformed component in many dedifferentiated/high-
grade transformed EMC, whereas α-SMA was rarely detected
and calponin negative [5, 10, 45, 46, 50]. It should be
emphasized that neoplastic myoepithelial cells present a
great plasticity in terms of immunoprofile and in EMC,
even the conventional tumors show differences regarding
the expression of myoepithelial markers [48]. In these, p63
expression is more frequently encountered than SMA.
3.2. Other Markers. The immunoprofile of the dedifferenti-
ation/high-grade transformation in salivary gland tumors
has been evaluated in many studies (Table 1), however,
with variable and therefore inconclusive results, possibly
due to the small number of cases. The marker that best
distinguished between the transformed and the conventional
components was Ki-67, since, in all salivary gland tumors
studied, an increased proliferation index was detected in the
transformed component when compared to the conventional
counterpart [2, 3, 5, 8, 9, 11, 12, 18, 21, 22, 25, 27, 28, 36, 45,
48, 49, 54]. However, a distinct cut-off for the proliferation
index that could identify the transformed component has
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Figure 3: Mucoepidermoid carcinoma with dedifferentiation to undifferentiated carcinoma. (a) and (b), Conventional component; (c)
dedifferentiated component. (a) PAS original magnification 400x; (b) H&E original magnification 100x; (c) H&E original magnification
200x.
yet to be established and probably it is variable among
the different types of tumors. The expression of p53 in
the transformed areas showed, in most of the cases and
in most of the salivary tumor types, higher levels than in
the conventional areas. Nevertheless, Di Palma et al. (1999)
and Henley et al. (1997) showed negative expression of
this protein in the dedifferentiated/high-grade component
of AcCC [35, 36]. Fonseca et al. and Sarode et al. also
showed lack of specificity to p53 in both components of
their cases of EMC [49, 50]. These inconsistent results
suggest that TP53 alteration is not the only mechanism for
transformation in salivary gland tumors but may indicate a
poor prognosis, similar to what is known for conventional
AdCC [58]. Cyclin D1 is an important regulator of the G1
phase of cell cycle [59]. Positive expression was observed
in dedifferentiated/transformed and conventional area of
AdCC, AcCC, and EMC [5, 8, 9, 21, 25, 28]. However,
in the MEC, Subramaniam et al. did not find positive
expression in the dedifferentiated area [54]. The precise
mechanisms responsible for the observed cyclin D1 overex-
pression in dedifferentiated/high-grade transformed salivary
gland tumors (Table 1) are not fully established; a role in
dedifferentiation of AdCC has been suggested in early studies
[2, 21]. Gene amplification of cyclin D1 might contribute, as
has been described in conventional AdCC [60].
Many other markers such as b-catenin [9], E-cadherin
[27], pRB [28], BCL2 [18], and glucose transporters
(GLUT) have been studied in individual tumors and
deserve to be analyzed in other salivary gland tumors
with dedifferentiation/high-grade transformation. GLUT1
has been considered a key molecule regulating the transport
and metabolism of glucose. Overexpression of GLUT1 has
been correlated with poor prognosis, tumor aggressiveness,
and lymph node metastases [61]. Bonfitto et al. showed
increased expression of GLUT1 in the transformed area when
compared to conventional area of AdCC, suggesting a change
in metabolic state of cancer cells imposing an increased
utilization of energy. However, the authors did not find any
correlation between GLUT1 expression and clinical outcome
[11]. In summary, the immunohistochemical differences
between the conventional and transformed areas require
further studies.
4. Molecular Profile
Studies on the genetic changes in salivary gland tumors with
dedifferentiation/high-grade transformation are rare. Only
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Table 1: Immunoprofile of dedifferentiated/high-grade transformed areas in salivary gland tumors.
Antibodies
Immunoprofile of high-grade transformed areas
AdCC AcCC EMC PLGA MEC MCa
Proliferative antigen
Ki-67 HI HI HI HI HI HI
Cytokeratins
AE1-AE3 + +/F + + +/− F
CAM 5.2 + NA +/F + − NA
34bE12 + NA F NA NA NA
CK 5/6 NA − + NA NA NA
CK 7 NA − +/− + NA NA
CK 14 −/F − −/F NA NA NA
CK 20 NA − NA − NA NA
Myoepithelial cell
S-100 +/F/− +/− +/F/− +/− − −
α-SMA (alfa-smooth
muscle actin)
−/F − −/F − − −
p63 −/F NA +/F/− +/− NA NA
Vimentin NA + +/− +/− NA +
Calponin F − − −/F NA NA
HHF35 (muscle-specific
actin)
−/F NA − NA NA NA
Desmin NA NA − − NA NA
Cell cycle control
p53 HI/+ HI/− +/− HI HI/F +
Cyclin D1 +/F HI + NA NA +
Membrane receptors
C-kit (CD117) +/− − NA NA − NA
HER2/neu (c-erbB2) +/− + − + − NA
EMA (epithelial membrane
antigen)
+ NA + + + NA
Structural proteins
GFAP (glial fibrillary acidic
protein)




−/F NA + +/− − NA
Steroid receptor
Androgen receptor − − NA +/F NA NA
+: positive expression; −: negative expression; F: focal expression; NA: not available; HI: higher index than in conventional area; AdCC: adenoid
cystic carcinoma; AcCC: acinic cell carcinoma; EMC: epithelial-myoepithelial carcinoma; PLGA: polymorphous low-grade adenocarcinoma; MEC:
mucoepidermoid carcinoma; MCa: myoepithelial carcinoma.
few cases have been demonstrated to carry mutations or
deletions in TP53 gene by loss of heterozygosity (LOH),
polymerase chain reaction (PCR), and microarray compar-
ative genomic hybridization (CGH) [9, 12, 21, 28, 35, 36].
However, p53 positive immunostaining is often indicative
of mutations in TP53 and was observed in the transformed
component in all tumor types studied [2–5, 8, 9, 11, 12,
18, 21, 22, 25, 27, 28, 54]. Therefore, the evidence suggests
that p53 abnormalities may be implicated in the process of
dedifferentiation, although its real importance in this process
should be clarified by further molecularstudies.
Fluorescence in situ hybridization (FISH) analysis did
not demonstrate gene amplification in the transformed
area with mild overexpression of HER-2/neu protein in
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acinic cell carcinoma [9]. DNA content has been studied
only in dedifferentiated/high-grade transformed AcCC and
EMC. Aneuploid AcCCs were associated with poor clinical
outcome whereas no aneuploid tumor was found in the EMC
group [31, 35, 36].
Using a high-resolution microarray CGH analysis in
AdCC with high-grade transformation, a correlation bet-
ween the number of chromosomal aberrations and the
degree of gland differentiation of the transformed com-
ponent was found. The AdCC with transformation in
moderately differentiated carcinomas carried one single
abnormality, whereas the AdCC with transformation in
poorly differentiated carcinomas showed a higher number
of alterations. These findings suggest that the AdCC with
high-grade transformation may not necessarily reflect a more
advanced stage of tumor progression, but rather a trans-
formation to another histological form, which encompasses
a wide spectrum of carcinomas in terms of aggressiveness
[12]. A comparison of the microarray CGH results of the
transformed and the conventional components in two cases
of AdCC with high-grade transformation (unpublished data
on cases in [12]) showed identical genetic profiles. A search
in the literature shows that this finding is not unusual.
Among others, examples are dedifferentiated liposarcomas
and biphasic carcinosarcomas [62, 63]. This indicates that
the genetic abnormalities have been acquired early in
tumorigenesis, or at least before the start of the phenotypic
change. It may be speculated that the genetic changes not
detectable by microarray CGH analysis such as mutation or
epigenetic silencing underlie the phenotypic change.
In conclusion, the dedifferentiation/high-grade transfor-
mation in salivary gland tumors seems to be a more complex
process than simple progression through histological grades.
Currently, the most useful tool in identifying the trans-
formed component is still a combination of morphological
criteria aided by Ki67 expression analysis.
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